Hypoechoic versus hypervascular lesion in the diagnosis of prostatic carcinoma

Publication date: Available online 17 August 2018Source: African Journal of UrologyAuthor(s): A.I. Ebeid, A.S. ElshamyAbstractObjectiveThe goal of this study was to get a better understanding the role of Power Doppler (PDUS) and conventional Gray Scale transrectal ultrasound (TRUS) in targeting prostatic biopsy in men with high prostate-specific antigen (PSA).Patients and methodsA prospective comparative study of 100 men, categorized according to PSA level into two groups: Group (A) with a PSA level (4.0–10.0) ng/ml (Gray zone) and Group (B) with PSA>10.0 ng/ml, above Gray zone. Gray Scale scanning was done, followed by Color Doppler and Power Doppler to test the blood flow all over the prostate and suspicious foci. Twelve systematic TRUS-guided core needle biopsies were performed, and additional biopsies of abnormal lesions on Gray Scale TRUS and PD-TRUS. The demographic data, clinical data, imaging results, laboratory investigations, histopathological report and its correlation with pathological results and any complications during or post the procedure estimated.ResultsThe age of the Group (A) ranged between 50 and 75 years with a mean ± S.D. of 65.7 ± 6.8 years, while in the Group (B), it ranged between 54 and 84 years with a mean ± S.D. of 69.5 ± 6.3 years. TRUS biopsy revealed prostate cancer in 11 (35.5%) out of 31 cases of the Group (A) and 35 (50.7%) out of 69 cases of the Group (B) (p 
Source: African Journal of Urology - Category: Urology & Nephrology Source Type: research

Related Links:

Conditions:   Castration-Sensitive Prostate Carcinoma;   Metastatic Prostate Carcinoma;   Stage IV Prostate Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8 Interventions:   Drug: Abiraterone Acetate;   Drug: Antiandrogen Therapy;   Drug: Apalutamide;   Drug: Prednisone;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration Sponsors:   OHSU Knight Canc...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
ConclusionThis case report describes a brain metastasis of a rare aggressive type of prostate cancer with poor prognosis. With metastatic lesions of prostatic adenocarcinoma, the probability of NE transdifferentiation increases. LCNEC has a poor prognosis attributed to its nature and late diagnosis. Thus, reporting and investigating such tumor will positively contribute to better management for future patients
Source: International Journal of Surgery Case Reports - Category: Surgery Source Type: research
We report a case of an 83-year-old man with castration-resistant prostate cancer in whom a metastasis to the thyroid cartilage was the only site of relapse.
Source: Clinical Nuclear Medicine - Category: Nuclear Medicine Tags: Interesting Images Source Type: research
We present the case of a 69-year-old man with history of prostate carcinoma treated with prostatectomy and subsequently with external beam radiotherapy and hormone therapy because of biochemical recurrences. More than 10 years after the diagnosis, follow-up 99mTc-HDP bone scans and SPECT/CT images demonstrated an incidental diagnosis of osteoblastic pleural plaques that quickly evolve to mesothelioma. PET/CT achieved the definitive diagnosis by guiding the biopsy to the highest and most accessible focus of glucidic hypermetabolism. Our case report raises the association between prostate cancer patients treated with externa...
Source: Clinical Nuclear Medicine - Category: Nuclear Medicine Tags: Interesting Images Source Type: research
68Ga-PSMA PET/CT imaging is an emerging imaging modality in prostate cancer. PSMA expression is also reported for nonprostate malignancies, including primary hepatocellular carcinoma. Herein, we present a case of a 74-year-ald man with recently diagnosed hepatocellular carcinoma who was referred for 18F-FDG PET/CT imaging for initial staging. The patient underwent 18F-FDG PET/CT as part of staging procedure; he also underwent 68Ga-PSMA PET/CT. PET/CT images revealed only slight 18F-FDG uptake in the liver lesion, but intense 68Ga-PSMA uptake, without any metastatic lesion seen elsewhere in the body.
Source: Clinical Nuclear Medicine - Category: Nuclear Medicine Tags: Interesting Images Source Type: research
Publication date: Available online 5 February 2020Source: Biochimica et Biophysica Acta (BBA) - Molecular Basis of DiseaseAuthor(s): Ana Margarida Abrantes, Ana Salomé Pires, Lúcia Monteiro, Ricardo Teixo, Ana Rita Neves, Nuno Tiago Tavares, Inês Alexandra Marques, Maria Filomena BotelhoAbstractCarcinogenesis is a complex multistep process, characterized by changes at different levels, both genetic and epigenetic, which alter cell metabolism. Positron emission tomography (PET) is a very sensitive image modality that allows to evaluate oncometabolism. PET functionalities are immense, since by labelling a...
Source: Biochimica et Biophysica Acta (BBA) Molecular Basis of Disease - Category: Molecular Biology Source Type: research
Conditions:   Metastatic Prostate Carcinoma;   Stage IV Prostate Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8 Interventions:   Behavioral: Questionnaire;   Procedure: Biospecimen Collection;   Diagnostic Test: Genetic Testing;   Other: Genetic Counseling;   Other: Laboratory Biomarker Analysis Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI) Enrolling by invitation
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Abstract Prostate cancer is difficult to treat if it metastasizes to other organs. The development of prostate cancer independent of androgen is closely related to the action of neuroendocrine products. Serotonin promotes cell growth in various cancers, and antagonists for serotonin receptors are known to inhibit proliferation and induce cell death in various carcinomas. However, little is known about how antagonists for serotonin receptor function in prostate cancer. We verified apoptotic cell death in prostate cancer cell lines after treatment with methiothepin mesylate (MET), an antagonist for serotonin recepto...
Source: Free Radical Biology and Medicine - Category: Biology Authors: Tags: Free Radic Biol Med Source Type: research
RARITAN, N.J., February 3, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today multiple data presentations from a robust solid tumor portfolio that will be featured at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place February 13-15 in San Francisco. Company-sponsored data presentations will include clinical results for ERLEADA® (apalutamide) and niraparib in prostate cancer; and BALVERSA™ (erdafitinib) in bladder cancer. “We are committed to improving outcomes in patients with prostate and bladder cancer where high unmet ...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
ConclusionsWe demonstrate for the first time that RAI16 is a direct target gene of AR. RAI16 may involved in cell growth of prostate cancer cells in response to AR signaling.
Source: Molecular and Cellular Endocrinology - Category: Endocrinology Source Type: research
More News: African Health | Cancer | Cancer & Oncology | Carcinoma | Laboratory Medicine | PET Scan | Prostate Cancer | Study | Ultrasound | Urology & Nephrology